Last reviewed · How we verify
Genrix (Shanghai) Biopharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
6 Phase 3
1 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| GR1501 high dose | GR1501 high dose | phase 3 | PD-1 inhibitor | PD-1 | Oncology | |
| GR2001 | GR2001 | phase 3 | ||||
| GR1801 | GR1801 | phase 3 | ||||
| GR1802 injection | GR1802 injection | phase 3 | PD-1 inhibitor | PD-1 | Oncology | |
| GR1501 low dose | GR1501 low dose | phase 3 | ||||
| GR1803 | GR1803 | phase 3 | Bispecific antibody | Oncology |
Therapeutic area mix
- Oncology · 4
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Amgen · 3 shared drug classes
- Sanofi · 3 shared drug classes
- Pfizer · 3 shared drug classes
- Janssen Research & Development, LLC · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- Hoffmann-La Roche · 2 shared drug classes
- Bristol-Myers Squibb · 2 shared drug classes
- Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Genrix (Shanghai) Biopharmaceutical Co., Ltd.:
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. pipeline updates — RSS
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. pipeline updates — Atom
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Genrix (Shanghai) Biopharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genrix-shanghai-biopharmaceutical-co-ltd. Accessed 2026-05-16.